Previous 10 | Next 10 |
Onconova Therapeutics ( NASDAQ: ONTX ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$0.21 and the consensus Revenue Estimate is $0.07M (+16.7% Y/Y). Over the last 1 year, ONTX has beaten EPS...
NEWTOWN, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to relea...
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be partici...
Onconova Therapeutics ( NASDAQ: ONTX ) said updated data from a phase 1/2a trial of oral rigosertib and Bristol-Myers Squibb's ( NYSE: BMY ) Opdivo (nivolumab) showed early signs of efficacy in certain extensively pre-treated patients with non-small c...
Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patients Responses achieved in patients with 3 distinct and different KRAS mutations, confirming the MOA of rigosertib bei...
NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be partici...
2Q22 Onconova Reported Trial Progress. 2Q22 loss of $4.0 million or $(0.19) per share, compared with our estimated loss of $3.7 million or $(0.18) per share. Several clinical trials for both narazaciclib and rigosertib are continuing as expected. The company ended the quarter with $46.5 millio...
Onconova Therapeutics, Inc. (ONTX) Q2 2022 Earnings Conference Call August 11, 2022 16:30 ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Steve Fruchtman - President & Chief Executive Officer Mark Gelder - Chief Medical Officer ...
Onconova Therapeutics press release ( NASDAQ: ONTX ): Q2 GAAP EPS of -$0.19 beats by $0.01 . Revenue of $0.06M in-line (flat Y/Y). Cash and cash equivalents as of June 30, 2022, were $46.5M, compared with $55.1M as of December 31, 2021. The company believes tha...
NEWTOWN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three m...
News, Short Squeeze, Breakout and More Instantly...
Onconova Therapeutics Inc. Company Name:
ONTX Stock Symbol:
NASDAQ Market:
Onconova Therapeutics Inc. Website:
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onco...
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines Funding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; tra...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...